Kevin M. Grant

My focus

I have extensive experience advising private investment funds and strategic buyers in acquisitions, divestitures, and other complex business transactions, with a particular focus on the middle-market. This includes counseling clients in structuring and negotiating leveraged buyouts, growth equity investments, venture investments, minority recapitalizations, and distressed and other special opportunities.

In addition, I work with private companies and financial sponsors in the management of their portfolio companies on a variety of corporate matters, including add-on acquisitions, debt financings, licensing, and international expansions. Further, I regularly represent entrepreneurs, and emerging and growth stage companies throughout the life cycle of the business, including capital raises and liquidity events.

Finally, I advise fund sponsors and family investment offices in formation of committed capital funds and special purpose vehicles. My corporate transactions work includes clients in many innovative industries, including life sciences, biomaterials, chemicals, manufacturing, technology, gaming, and consumer.

Representative experience

Kevin joined Nixon Peabody in March 2022. The work listed here may reflect experience from prior firms.

• SK Capital Partners in the sale of its portfolio company, Tri-Tex, a specialty chemicals company
• Equity investment by a financial sponsor, debtor in possession financing, and subsequent acquisition in a bankruptcy section 363 sale of Hair Cuttery salons
• Debtor in possession financing and acquisition in a bankruptcy section 363 sale of New York Sports Clubs and related assets
• Equity financing of Pow! Interactive, a gaming holding company, and acquisition of Jasco Games
• Sale of Veterinary Care Group, a network of veterinary clinics, to National Veterinary Associates
• Salona Global Medical Device Corp in its acquisitions of Simbex and South Dakota Partners
• Sale of Curalate, Inc., a visual commerce solutions provider, to Bazaarvoice
• SK Capital Partners in its acquisitions of:
  • Foremark Performance Chemicals
  • Tri-Tex Co.
  • Noramco and Tasmanian Alkaloids
  • Halo Pharmaceutical
• SK Capital Partners in its divestiture of the US operations of IBA Molecular and subsequent sale of remaining ex-US business of IBA Molecular
• BTG plc in its investment and option to acquire Veran Medical
• BTG plc in its acquisitions of:
  • Novate Medical
  • EKOS Corporation
  • PneumRx
  • Galil Medical
  • Roxwood Medical

Looking ahead

I see the middle-market remaining robust, with financial sponsors building on platform acquisitions with add-ons in key verticals. On the strategic side, international companies remain acquisitive and continue to seek expansion, growing through acquisitions in the US and abroad.